ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 975

Functional Impairment of Mitf and the MiT Transcription Factor Family Dysregulates B Cell Activation and Function

Abhimanyu Amarnani1, Ramile Dilshat 2, Nikita Malakhov 3, Brian Ghezelaiagh 4, Chongmin Huan 1, Erna Magnusdottir 2, Eirikur Steingrimsson 2 and Christopher Roman 1, 1SUNY Downstate Medical Center, Brooklyn, 2University of Iceland Biomedical Center, Reykjavik, Iceland, 3SUNY Downstate Medical Center, New York Presbyterian-Weill Cornell Medical Center, Brooklyn, 4SUNY Downstate Medical Center, Stony Brook University, Brooklyn

Meeting: 2019 ACR/ARP Annual Meeting

Keywords: Auto-immunity, B cell tolerance and B cells, SLE

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 11, 2019

Title: B Cell Biology & Targets In Autoimmune & Inflammatory Disease Poster

Session Type: Poster Session (Monday)

Session Time: 9:00AM-11:00AM

Background/Purpose:

Autoreactive B cells are central in the development of many autoimmune diseases, such as systemic lupus erythematosus (SLE), and are normally eliminated or inactivated by B cell tolerance mechanisms. Our lab developed a mouse model, called TDN-B, whereby inhibition of the microphthalmia transcription factor (MITF) and its family members, TFE3, TFEB, and TFEC occurs specifically in B cells. Prior work showed that B cell homeostasis and tolerance were compromised in this model, as evidenced by splenomegaly, elevated autoantibody titers, and altered B cell compartments. Further, this model worsened SLE-like disease when superimposed on an SLE-susceptible genetic background (B6.lpr), driving accelerated mortality, production of pathologic autoantibodies, and hastened renal disease. To define the signaling pathways regulated by Mitf and the MiT family that could explain their involvement in B cell tolerance, the presented work evaluated the TDN-B model, and a genetic model in which Mitf was not expressed in any cell type (Mitfmi-vga9).

Methods:

B cell and T cell subsets were characterized by flow cytometry of bone marrow and spleen, serum immunoglobulin and autoantibody serum titers were quantified by ELISA, in-vitro isolated B cell cytokine secretion was quantified by Luminex, B cell and T cell organization within splenic follicles was visualized through wide-field and confocal microscopy, and comprehensive investigation of mRNA expression in ex-vivo B cells was defined through RNA sequencing. All experiments compared TDN-B, Mitfmi-vga9, and wildtype mice.

Results:

Both TDN-B and Mitfmi-vga9 mice showed increased serum rheumatoid factor, splenomegaly, increased numbers of splenocytes, and disorganization of splenic follicles. Uniquely, Mitfmi-vga9 mice, with Mitf absent in all cells, showed increased serum levels of IgG anti-dsDNA, increased splenic germinal center (GC) B cells, and increased splenic plasma cells (PCs). While increased splenic GC B cells and PCs were not observed in TDN-B mice, increased numbers of pre-B/immature B cells and PCs were observed in the bone marrow. RNA sequencing of ex-vivo B cells showed that in both models, upregulated mRNA pools were significantly enriched for genes with roles in GC growth and/or regulation. Further, pathways related to regulation of cell cycle, MHCII antigen presentation, and cytokine signaling were all significantly enriched for in mRNA from both Mitfmi-vga9 and TDN-B B cells. Additional experiments in Mitfmi-vga9 mice uniquely demonstrated increased numbers of B cells with surface expression of activation markers (CD69, CD25) and antigen presentation molecules (MHCII, CD86), and that B cells in culture had increased secretion of TNF-alpha after LPS stimulation.

Conclusion:

These data demonstrate that the functional impairment of Mitf and the MiT transcription factor family results in a breach of B cell tolerance that is coincident with cellular and molecular changes, which lead to dysregulation of B cell activation, antigen presentation, cytokine secretion, germinal center organization, plasma cell differentiation, and autoantibody production. The underlying mechanisms responsible for these effects are under investigation.


Disclosure: A. Amarnani, None; R. Dilshat, None; N. Malakhov, None; B. Ghezelaiagh, None; C. Huan, None; E. Magnusdottir, None; E. Steingrimsson, None; C. Roman, None.

To cite this abstract in AMA style:

Amarnani A, Dilshat R, Malakhov N, Ghezelaiagh B, Huan C, Magnusdottir E, Steingrimsson E, Roman C. Functional Impairment of Mitf and the MiT Transcription Factor Family Dysregulates B Cell Activation and Function [abstract]. Arthritis Rheumatol. 2019; 71 (suppl 10). https://acrabstracts.org/abstract/functional-impairment-of-mitf-and-the-mit-transcription-factor-family-dysregulates-b-cell-activation-and-function/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2019 ACR/ARP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/functional-impairment-of-mitf-and-the-mit-transcription-factor-family-dysregulates-b-cell-activation-and-function/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology